Bone mineral density (BMD) is usually normal at the time of inflammatory bowel disease (IBD) diagnosis. The purpose of this study was to evaluate the role of vitamin D metabolism in recently diagnosed IBD.
INTRODUCTION
A higher incidence of osteoporosis and fractures is a recognized complication of inflammatory bowel disease (IBD) (1) . Population-based studies confirm that IBD patients have a 21-40% greater risk of fractures compared with the general population (2) (3) (4) . Multiple factors have been implicated including nutritional deficiencies, systemic inflammation, malabsorption, and corticosteroid use (5) .
The role of vitamin D insufficiency in IBD-related bone disease is uncertain. Vitamin D insufficiency has gained considerable attention in recent years following observations that vitamin D status is suboptimal in a large fraction of healthy and osteoporotic individuals worldwide (6, 7) . Although the definition of optimal vitamin D status is still open to debate, many experts now define the beginning of the normal range as the serum 25-hydroxy vitamin D (25OHD) level associated with a serum PTH, which is not further suppressed by increasing vitamin D intake. This translates to an optimal lower limit of 25OHD of 75 nmol/L (8, 9) . This is also the approximate range where increases in intestinal calcium absorption and lower extremity muscle function appear to plateau (10, 11) .
Several reports indicate that bone mineral density (BMD) is usually normal in individuals with newly diagnosed IBD but may be followed by a period of accelerated bone loss (12) (13) (14) . Whether vitamin D insufficiency contributes to reduced BMD in early IBD had not been investigated. This has significant clinical implications since vitamin D supplementation is easy and inexpensive, with a high safety profile.
The Manitoba IBD Cohort Study is a research program with the aim of defining multiple health outcomes and their determinants in persons with IBD. Skeletal health in IBD was one of the primary research themes and the current analysis was undertaken to determine the association between BMD and vitamin D status at baseline and followup in a population-based cohort of recently diagnosed IBD patients.
METHODS

Patient Population
The study design and patient population have been previously reported in detail (15) . Briefly, individuals within 7 yr of IBD diagnosis were identified from the University of Manitoba IBD Research Registry, the largest population-based registry of IBD in North America. The University of Manitoba IBD Epidemiology Database and the University of Manitoba IBD Research Registry were created in 1995 (16) . Patients eligible for inclusion were identified through the population-based administrative health registry of Manitoba Health (the single provincial health insurer that provides comprehensive coverage to all residents of Manitoba) using an administrative definition of IBD that was validated by random sample chart reviews. Questionnaires were mailed to patients identified in the Manitoba Health registry, and those who agreed to be included in a research registry and to be contacted for future IBD-related research studies were included in the University of Manitoba Inflammatory Bowel Disease Research Registry. This methodology was repeated in 2000 to enhance the numbers of patients in the Research Registry.
Individuals within 7 yr of IBD diagnosis and who were 18 yr of age or older (N = 606) were identified from the Registry and were invited to participate in the study. A total of 418 (69.0%) individuals initially responded. Following this initial contact, 19 individuals did not respond to the request to complete the baseline survey, another four individuals withdrew, and seven individuals were found to be ineligible, resulting in a final sample of 388 participants for the Manitoba IBD Cohort Study. From the initial study population, a subset was randomly selected for participation in more detailed investigations of bone health. All assessments were performed in nonwinter months. The objective was to recruit 100 participants stratified by age (<50 yr vs >50 yr) in equal proportions. Exclusion criteria for the bone substudy included current or recent pregnancy (within 6 months), current or recent breast feeding (within 6 months), and other disorders known to affect bone metabolism independent of IBD and its treatment (rheumatoid arthritis or other inflammatory joint disease, thyroid disease, parathyroid disease, primary bone disease, severe neurologic disease impairing ambulation, noncutaneous malignancies, liver disease, eating disorder, or renal dysfunction with serum creatinine >0.150 mmol/L). Individuals that completed the baseline measurements were invited to return for follow-up BMD measurements 2.3 ± 0.3 yr later. The study protocol was approved by the University of Manitoba Research Ethics Board and all participants provided signed informed consent.
Measurements
All subjects underwent measurement of lumbar spine, hip, and total body BMD with dual-energy x-ray absorptiometry (DXA) (Hologic QDR-4500, Waltham, MA). Scans were acquired and analyzed using manufacturer specifications and white reference data to provide standard measures of areal BMD including T-scores and Z-scores. T-scores and Z-scores used sex-matched reference data (except for the total body, for which male reference data are not available). In accordance with BMD reporting recommendations from the International Society of Clinical Densitometry (ISCD), abnormal BMD was defined as T-score < -2.5 in participants aged 50 yr or older, and by a Z-score < -2.0 if aged less than 50 yr (17, 18) . All results were reviewed by a single study investigator with extensive experience in clinical and research DXA (WDL). Daily quality control of the DXA device gave long-term precision error <0.5% and the in vivo coefficient of variation [CV] was 1.0-1.7% for the measurement sites.
Serum was collected for measurement of 25OHD, parathyroid hormone (PTH), creatinine, calcium, phosphate, albumin, total alkaline phosphatase (tALP), bone-specific alkaline phosphatase (BSAP), and N-telopeptide (NTX). Serum 25OHD was measured using a radioimmunoassay that detects both the D 2 and D 3 metabolites of vitamin D (Diasorin Inc., Stillwater, MN) by a lab that participates in DEQAS Quality Assurance Program for vitamin D (interassay CV 6-13%). Intact PTH was measured using an enzyme immunoassay (Diagnostics Products Corporation, Los Angeles, CA) run on an Immulite system (CV 9%).
Statistics
Univariate analyses were used to compare groups (χ 2 test for categorical data and Student's t-test for continuous data). The association between continuous variables was assessed using simple and multiple linear regression. Analysis of covariance (ANCOVA) was used to test and exclude interactions with age and the underlying diagnosis. Serum 25OHD was categorized according to quartiles and also using prespecified cutoffs as deficient (<25 nmol/L), insufficient (25-49 nmol/L), marginal (50-74 nmol/L), and optimal (>75 nmol/L). Multiple analysis of variance (MANOVA) was used to explore the relationship between 25OHD category and BMD measurements. Post hoc subgroup comparisons were performed using Tukey's test. Continuous data are expressed as mean ± SD unless otherwise stated. All statistical analyses were performed with Statistica version 7.1 (Statsoft, Inc., Tulsa, OK). A P value of less than 0.05 was used to determine statistical significance.
RESULTS
Population
Baseline bone measurements were obtained in 101 subjects as described in Table 1 . The median time since IBD diagnosis was 4 yr. There were slightly more women than men (59 [58%] vs 42 [42%]), which was comparable with the sex distribution in the overall study population. There was a similar number of individuals with Crohn's disease (56 [55%]) vs ulcerative colitis/proctitis (45 [45%]) in the bone substudy participants, and the proportion was similar to the overall study population. By design, one-half of the bone substudy participants were less than age 50 at the time of recruitment and the remainder were over age 50. The mean age (47 ± 16 yr) was slightly older than in the overall study population, reflecting the age-stratified recruitment to the bone substudy. Women were slightly younger than men (45 ± 14 yr vs 50 ± 17 yr, P = 0.07) but the difference was not statistically significant. BMI was equal for men and women (28.7 ± 6.0 kg/m 2 vs 27.8 ± 6.8 kg/m 2 , P = 0.49). Most of the subjects (61 [60%]) reported a history of prior corticosteroid use. The median age at first corticosteroid exposure was 40 yr (interquartile range 28-51) with a median cumulative exposure of 4 months (interquartile range 2-9). Of the 101 participants, 17 (17%) admitted to current or past use of one or more bone-sparing medications (15 estrogen, 4 bisphosphonate, 4 raloxifene, 4 parenteral calcitonin). Self-reported disease activity based on the 6 months prior to the baseline visit was categorized as active in 24 (24%) of the participants and inactive in the remainder. Mean ± SD. BMD = bone mineral density; CD = Crohn's disease; UC = ulcerative colitis/proctitis; 25OHD = 25-hydroxy vitamin D; PTH = parathyroid hormone; tALP = total alkaline phosphatase; BSAP = bone-specific alkaline phosphatase; NTX = N-telopeptide. †Abnormal defined as T-score < -2. 
Baseline Measurements
Baseline skeletal measurements are summarized in Table 2 . Mean Z-scores for the lumbar spine (-0.14 ± 1.25) and total hip (0.08 ± 0.99) indicate BMD close to the age-matched mean. Men had lower lumbar spine Z-scores than women (P < 0.01) but total hip results were similar. Participants younger than age 50 yr had lower Z-scores for all sites compared with those aged 50 and older (all P < 0.01), and this persisted after ANCOVA adjustment for weight and cumulative corticosteroid use (all P < 0.05). Mean T-scores for the lumbar spine and total hip did not differ according to sex or age stratum. Total body T-scores and Z-scores were lower in women than men, which may relate to the lack of male reference data. A diagnosis of Crohn's disease compared with ulcerative colitis/proctitis was associated with lower total hip and total body Z-scores, but lumbar spine Z-scores were similar. Nine (9%) of the subjects had at least one abnormal measurement (8 lumbar spine, 2 total hip, and 1 total body). No significant difference in the distribution of abnormal bone density measurements was seen according to sex, age stratum, or diagnosis. The mean serum 25OHD was 58.6 ± 25.4 nmol/L, and was similar for different sex and age strata. Mean 25OHD levels for the fall months (50.2 ± 19.3 nmol/L, N = 37) were lower than those from the spring (64.1 ± 28.5 nmol/L, N = 42) or summer (62.3 ± 25.5 nmol/L, N = 22; ANOVA P = 0.038) months. Serum 25OHD did not differ between subjects with Crohn's disease (59.1 ± 28.1 nmol/L) and those with ulcerative colitis/proctitis (58.1 ± 21.8 nmol/L). Serum 25OHD did not differ between subjects with prior corticosteroid exposure (60.0 ± 26.6 nmol/L) versus those without corticosteroid exposure (59.0 ± 2.7 nmol/L). In subjects with prior corticosteroid exposure, there was no significant correlation between serum 25OHD and age at first corticosteroid exposure (P = 0.28) or cumulative exposure (P = 0.14). Serum 25OHD was similar in the participants with active and inactive disease (58.9 ± 23.5 vs 57.9 ± 26.1 nmol/L, P = 0.87). 8%) . Mean values for the other biochemical parameters were within the laboratory reference ranges. Serum 25OHD was unrelated to age, sex, weight, or BMI (all P > 0.2). Serum creatinine was slightly higher in men than women, and in the older age stratum. Serum calcium was slightly lower in the younger age stratum while serum phosphate was slightly greater. As expected, there was an inverse correlation between serum 25OHD and PTH (r = -0.42, P < 0.001) ( Table 3 ). In turn, serum PTH was positively correlated with all markers of bone turnover (tALP r = 0.28, P < 0.01; BSAP r = 0.25, P < 0.05; NTX r = 0.25, P < 0.05). In addition, serum 25OHD showed a positive association with serum albumin (r = 0.30, P < 0.01).
Correlates of BMD
Several of the biochemical parameters showed significant associations with baseline bone density (Table 4 ). Higher serum 25OHD was associated with greater bone density at all sites (lumbar spine r = 0.28, P < 0.01; total hip r = 0.21, P < 0.05; total body r = 0.21, P < 0.05) and this was unchanged after adjustment for seasonal differences (lumbar spine r = 0.31, P < 0.01; total hip r = 0.24, P < 0.05; total body r = 0.23, P < 0.05) and was unaffected by the underlying diagnosis (P > 0.1 for all interaction terms). Each SD decrease in serum 25OHD was associated with a 3.4% reduction in spine BMD, a 2.9% reduction in total hip BMD, and a 2.0% reduction in total body BMD. BMD showed a negative correlation with serum PTH and all markers of bone turnover. There was a positive correlation between bone density at the total hip and total body and serum creatinine, and these were still statistically significant when adjusted for age and sex in multiple linear regression models (serum creatinine vs total hip BMD beta = 0.34, P < 0.01; serum creatinine vs total body BMD beta = 0.27, P < 0.05). Baseline BMD at all measurement sites was positively correlated with serum albumin. Baseline bone density was studied in relation to vitamin D status. When analyzed according to serum 25OHD quartile, MANOVA confirmed significant differences in baseline bone density (P < 0.05). There was a general trend of greater BMD for higher serum 25OHD subgroups (Fig. 1) , but in post hoc testing this was only statistically significant for quartile 2 versus quartile 4 (P < 0.05). There was a nonsignificant trend (P = 0.08) for differences in baseline bone density related to serum 25OHD categorized as deficient (<25 nmol/L), insufficient (25-49 nmol/L), marginal (50-74 nmol/L), and optimal (≥75 nmol/L). When the deficient (<25 nmol/L) subgroup was compared with higher levels of serum 25OHD (≥25 nmol/L), there was a significant difference in baseline BMD by MANOVA (P < 0.05).
Change in BMD
Of the original 101 participants undergoing BMD measurements, 94 (53 women and 41 men) returned for repeat measurements 2.3 ± 0.3 yr later. There was an increase in mean BMD at all measurement sites between the first and second scans: lumbar spine +0.017 ± 0.049 g/cm 2 (1.7%), total hip +0.003 ± 0.040 g/cm 2 (0.3%), and total body +0.003 ± 0.022 g/cm 2 (0.3%). The change was only statistically significant for the lumbar spine and may simply reflect age-related degenerative effects. No sex subgroup differences were seen in the change in bone density (data not shown). Subjects younger than age 50 had a larger increase in total body BMD than older subjects (+0.008 ± 0.021 g/cm 2 vs -0.002 ± 0.021 g/cm 2 , P < 0.05), but age subgroup was unrelated to change at the lumbar spine or total hip.
Gain in total body BMD between the baseline and followup DXA scans was positively correlated with serum 25OHD (r = 0.20, P < 0.05) ( Table 4) . Serum 25OHD was unrelated to BMD change at the lumbar spine or total hip. No correlation was observed between serum PTH and change in BMD at any site. Higher levels of BSAP and NTX showed an association with increasing bone density (P < 0.05 in 3 of 6 comparisons). Serum creatinine was correlated with a decrease in total hip BMD (r = -0.24, P < 0.05) and tALP was correlated with a decrease in total body BMD (r = -0.24, P < 0.05).
Parsimonious multiple linear regression models were constructed for predicting the change in BMD at each measurement site from age, osteoporosis medication use, serum 25OHD, creatinine, and a single bone turnover marker, NTX (Table 5 ). Disease activity was not included in these models since it did not show a significant univariate relationship with baseline BMD, change in BMD, serum 25OHD, or the other biochemical parameters (data not shown). For the lumbar spine and total hip, NTX (P < 0.05) was a significant independent predictor of change in BMD with higher NTX associated with a larger increase. Higher serum creatinine was independently associated with a greater decrease in total hip BMD (P < 0.01). For the change in total body BMD, only serum 25OHD showed a significant effect (P < 0.05) with higher values associated with a larger gain in BMD.
DISCUSSION
We have found that vitamin D status was associated with baseline BMD measurements in a population-based cohort with recently diagnosed IBD. There was a weaker association between baseline vitamin D status and change in total body BMD after a mean 2.3 yr of follow-up. Markers of bone turnover were predictive of baseline BMD at all sites and with change at the lumbar spine and total hip, whereas serum creatinine appeared to have an effect limited to the total hip. It is unclear if this inconsistency between sites relates to true biologic differences or simply the relatively small size of the cohort. Age-adjusted Z-scores were lower in younger than in older participants, and this was unrelated to weight or corticosteroid exposure. The mechanism and clinical significance of this finding are unknown and warrant further study. It is noteworthy that only a minority of the study participants (21.8%) had vitamin D status in the optimal range (75 nmol/L or greater). Our findings are not surprising given the well-established role of vitamin D on skeletal metabolism, although not all reports have found an association between vitamin D status and bone density (19, 20) . One study failed to find an association between vitamin D intake and BMD in premenopausal women, but serological assessment provides a more complete picture since it also reflects skin synthesis (20) . Several studies have documented stability or an increase in BMD in IBD patients given calcium and vitamin D supplements (21) (22) (23) (24) . These findings are consistent with observational studies (25) (26) (27) and randomized trials (28) (29) (30) (31) conducted in the general population that have found better vitamin D status to be associated with higher BMD. It should be noted that the terms vitamin D "deficiency" and "insufficiency" have not been defined with universal agreement, and vitamin D is usually regarded as a continuum encompassing both terms. Deficiency of vitamin D has been used to describe the advanced musculoskeletal effects of chronically low vitamin D: rickets in children and osteomalacia in adults. Vitamin D "insufficiency" is a milder form of deficiency, although the mild secondary hyperparathyroidism may cause greater bone turnover and bone loss.
Although this study has focused on the skeletal actions of vitamin D, this hormone also has important physiological actions outside of the musculoskeletal system (32) . Receptors for calcitriol and the enzyme involved in its synthesis (1-hydroxylase) are expressed by many tissues other than those concerned with calcium regulation, and in some tissues there appear to be important antiproliferative and prodifferentiating properties (33) . A recent systematic review yielded 63 observational studies of vitamin D status in relation to cancer risk (34) . The majority of these studies found a protective relationship between sufficient vitamin D status and lower risk of cancer. Of relevance to IBD patients, a meta-analysis of colorectal cancer found that individuals with 25 µg (1,000 IU) per day or more of oral vitamin D or serum 25OHD concentrations ≥82 nmol/L had a 50% lower incidence of colorectal cancer compared to reference values (35) . Recently, a 4-yr RCT conducted in 1,179 community-dwelling postmenopausal women showed that daily supplementation with calcium 1,400-1,500 mg and vitamin D 3 27.5 µg (1,100 IU) substantially reduced all-cancer risk (36) . Vitamin D is also involved in regulation of the immune system, and evidence is accumulating for its involvement in the pathogenesis of IBD (37) .
The advantage of our study was that it was conducted in a population-based sample of IBD patients who had relatively recent onset disease. Several limitations apply to our study. This was an observational study and therefore associations may not reflect causality. We did not include healthy controls and cannot say whether vitamin D status or BMD in our IBD patients differs from the general population. The Canadian population has a high prevalence of vitamin D insufficiency/deficiency (38) (39) (40) . In a population-based study of seasonal changes in 25OHD, 97% had 25OHD levels below 80 nmol/L in at least one of four measurements during the year (38) . Our results may have limited generalizability to geographic areas with different patterns of sun exposure. A global ecological study found that for each 10 degrees change in latitude from the equator, hip fracture probability increased by 0.6% (6) . Finally, biochemical analyses were based on a single measurement at baseline and may not reflect long-term vitamin D status.
We have confirmed previous reports that abnormal BMD is uncommon within the first few years after IBD diagnosis. Our findings also suggest that vitamin D supplementation is probably warranted for most IBD patients. In the absence of vitamin D supplementation, serum 25OHD should be measured. Markers of bone turnover may provide information on BMD that is independent of vitamin D status, but this requires further study. In summary, poorer vitamin D status correlates with lower baseline BMD and better vitamin D status is correlated with a gain in total body BMD. Early optimization of vitamin D may play an important role in preventing IBDrelated bone disease. r Each standard deviation decrease in serum 25OHD was associated with a 2.0-3.4% reduction in baseline BMD.
STUDY HIGHLIGHTS
r Gain in total body BMD was positively correlated with 25OHD.
